세계의 계산생물학 시장 규모는 2024년 68억 달러에 달했습니다. IMARC Group은 향후 시장 규모가 2033년까지 322억 달러에 이를 전망이며, 2025-2033년 17.83%의 성장률(CAGR)로 성장할 것으로 예측했습니다. 시장을 견인하는 것은 첨단 기술의 통합과 관련된 임상 연구 증가입니다. 현재 북미가 가장 큰 시장 점유율을 차지하고 있지만, 이는 주요 제약 기업 및 생명 공학 기업의 존재와 기업 간의 다양한 협력 관계 때문입니다.
계산생물학은 바이오인포매틱스라고도 불리며 수학, 통계학 및 컴퓨터 과학을 사용하여 생명의 구조와 과정을 이해하고 모델링하는 학제 간 과학의 한 분야입니다. 유전학, 진화학, 세포 생물학, 생화학 등 생물학의 다양한 측면을 포함합니다. 이 과정에서는 알고리즘을 포함한 계산 기술을 사용하여 생물학적 시스템을 표현하고 시뮬레이션하며 실험 데이터를 대규모로 해석합니다. 계산생물학은 또한 아미노산 배열, 뉴클레오티드, 고분자 구조로부터 생물학적 정보의 데이터베이스를 생성함으로써 질병의 치료 및 세포 기능을 이해하는 데 도움이 됩니다. 현재 계산생물학은 인간 유전체 프로젝트, 단백질 데이터 뱅크, 유전체 데이터베이스와 같은 생물학적 연구 프로젝트에 필수적입니다.
세계의 계산생물학 시장은 주로 약리 유전학 분야에서 임상 연구 증가에 의해 견인되고 있습니다. 이를 통해 환자 집단의 다양한 생물학적 구성, 생물학적 경로 및 이를 지원하는 유전체에 대한 이해가 깊어졌습니다. 그 결과, 계산생물학 솔루션은 창약 및 기타 다양한 과학 실험에 필요한 전체 시간을 단축하는 데 도움이 되므로 높은 수요가 있습니다. 이 과정은 고급 약물-약물 상호 작용을 시뮬레이트하는 도구를 시각화하는 데에도 도움이 됩니다. 이 외에도, 단백질의 구조 및 상호 작용을 해명하기 위한 에피유전체학, 단백질체학, 군유전체학에서 계산생물학 수요 증가도 시장의 성장을 뒷받침하고 있습니다. 또한 의약품 개발 및 질병 모델링의 다양한 기술적 진보와 민간 및 정부 기관의 연구개발 활동에 대한 투자 증가도 가까운 미래에 시장에 긍정적인 추진력을 줄 것으로 예측됩니다.
The global computational biology market size reached USD 6.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 32.2 Billion by 2033, exhibiting a growth rate (CAGR) of 17.83% during 2025-2033. The market is being driven by the rising number of clinical studies, along with integration of advanced technologies. At present, North America holds the largest market share, driven by the presence of leading pharmaceutical and biotechnology companies and various collaborations among companies.
Computational biology, also known as bioinformatics, is the interdisciplinary branch of science that uses math, statistics and computer science for understanding and modeling the structures and processes of life. It involves various aspects of biology, such as genetics, evolution, cell biology, and biochemistry. The process uses computational techniques, including algorithms, to represent and simulate biological systems and interpret experimental data on a large scale. Computational biology also helps understand the treatment for diseases and cellular function by creating a database of biological information from amino-acid sequences, nucleotides, and macromolecular structures. Nowadays, computational biology has become an essential part of biological research projects, including the human genome project, protein data banks and genomic databases.
The global computational biology market is primarily driven by the rising number of clinical studies in the field of pharmacogenomics. This has helped increase the understanding of the diverse biological makeup of the patient population, biological pathways, and the genomes underpinning them. As a result, there is a high demand for computational biology solutions, as they help reduce the overall time needed for drug discovery and various other scientific experiments. The process also aids the visualization of tools to simulate advanced drug-drug interactions. In addition to this, the growing demand for computational biology in epi-genomics, proteomics, and meta-genomics to undertint protein structures and interactions is also propelling the market growth. Furthermore, various technological advancements in drug development and disease modeling, along with increasing investments by private and government organizations in research and development (R&D) activities, are also anticipated to provide a positive thrust to the market in the near future.
Cellular and biological simulation accounts for the majority of the market share
Researchers can better comprehend basic biological processes and the course of disease by using cellular and biological modeling. Cellular simulations are essential to drug discovery because they allow for virtual chemical screening, drug interaction prediction, and lead candidate optimization. As a result, this reduces the time and cost associated with traditional experimental approaches. The accuracy and dependability of cellular and biological simulations are improved by the development of complex simulation software and algorithms such as agent-based modeling and systems biology techniques. A thorough grasp of biological activities is made possible by the integration of simulations with proteomic, metabolomic, and genomic data.
Contract holds the largest share of the industry
Contract services provide cost-effective solutions compared to maintaining in-house capabilities, particularly for smaller companies or those with limited resources. This trend is fostering more organizations to engage third-party providers for computational biology services. Contract service providers usually have access to the latest computational tools, technologies, and methodologies that allow clients to benefit from state-of-the-art solutions without the need for significant investment in infrastructure. Furthermore, contract services offer flexibility and scalability that allow companies to adjust the level of support based on project requirements.
Commercial represents the leading market segment
The creation of novel treatments is becoming a top priority for commercial enterprises, necessitating the use of sophisticated computational tools for biological system modeling, medication interaction prediction, and data analysis. The commercial segment is growing as a result of pharmaceutical and biotechnology businesses' substantial spending in research and development (R&D) activities. Computational biology solutions are being used by businesses more and more in order to obtain a competitive edge in drug discovery. The integration of data science and machine learning (ML) into drug development processes is leading to a higher adoption of computational biology techniques in commercial settings.
North America leads the market, accounting for the largest computational biology market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for computational biology.
North America is home to many leading pharmaceutical and biotechnology companies. The demand for computational biology solutions is significant in this region, as companies seek to streamline drug discovery and enhance their research and development (R&D) processes. The presence of well-established research institutions, universities, and laboratories equipped with advanced technologies fosters a conducive environment for computational biology. These institutions often collaborate with commercial entities, further driving the demand for computational services. Furthermore, top players in the region are developing new tools and methodologies that enhance research capabilities.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Certara, Chemical Computing Group ULC, Compugen Ltd, Dassault Systemes, Genedata AG, Insilico Biotechnology AG, Instem plc, Nimbus Therapeutics LLC, Schrodinger Inc. and Simulations Plus Inc.